Drug intelligence / Profile preview

99mTc-HYNIC-cHK

Development stage
Preclinical
Lead developer
Peking University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

99mTc-HYNIC-cHK is a technetium-99m labeled radiopharmaceutical designed for noninvasive imaging of integrin αvβ6 expression using single-photon emission computed tomography (SPECT). The tracer consists of a disulfide-cyclized peptide (cHK) conjugated to the bifunctional chelator 6-hydrazinonicotinic acid (HYNIC) and labeled with 99mTc. Integrin αvβ6 is a cell surface receptor that is significantly upregulated in various cancers, particularly pancreatic cancer, and in fibrotic conditions like idiopathic pulmonary fibrosis (IPF), while remaining nearly undetectable in normal tissues. Compared to its linear counterpart (99mTc-HYNIC-HK), the cyclic version demonstrates improved metabolic stability and higher tumor-to-muscle ratios, providing high-contrast images for disease diagnosis and therapy monitoring.

Other names
99mTc-labeled cyclic HK peptide99mTc-HYNIC-cyclic HK99mTc-HYNIC-c(HK)
02

Targets

αVβ6 (Integrin αVβ6)

Beyond the preview

Go deeper on 99mTc-HYNIC-cHK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-HYNIC-cHK.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call